Compare the Effects of a Standard Therapy Protocol With a 12-week Peri-Operative Program of Kneehab XP Neuromuscular Electrical Stimulation Compared to a Control Treatment in Patients Undergoing Total Knee Replacement
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | February 16, 2012 | ||||
| Last Updated Date | March 21, 2012 | ||||
| Start Date ICMJE | March 2012 | ||||
| Estimated Primary Completion Date | March 2013 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Isometric strength test [ Time Frame: measured at the 6 week post-operative time point ] [ Designated as safety issue: No ] To determine the efficacy of Kneehab XP in promoting early quadriceps strength improvement (measured at the 6 week post-operative time point) when compared to a control group in patients undergoing total knee arthroplasty. |
||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT01548040 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE |
|
||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Compare the Effects of a Standard Therapy Protocol With a 12-week Peri-Operative Program of Kneehab XP Neuromuscular Electrical Stimulation Compared to a Control Treatment in Patients Undergoing Total Knee Replacement | ||||
| Official Title ICMJE | A Randomised Controlled Study To Compare the Effects of a Standard Therapy Protocol With a 12-week Peri-Operative Program of Kneehab XP Neuromuscular Electrical Stimulation Compared to a Control Treatment in Patients Undergoing Total Knee Replacement | ||||
| Brief Summary | The study is a double-blind randomized controlled clinical trial.Approximately 118 patients (males and females) who are at least 40 years of age, who are scheduled for total-knee arthroplasty (TKA) surgery will be randomized into 1) a treatment group who receive Kneehab XP and a standard rehabilitation program and 2) a control group who receive only a sham device and a standard rehabilitation program. Patients are tracked for measures of function, pain, quality of life, physical performance and acceptable states status at 6 weeks and 1 week before surgery and 3, 6, 12, and 52 weeks following surgery. Hypothesis 1: The effect of 12-weeks of Kneehab XP (peri-operative NMES) combined with standard rehabilitation in patients undergoing TKA surgery will lead to increased quadriceps strength compared to a control group at the 6 week post-operative time point. Hypothesis 2: The effect of 12-weeks of Kneehab XP (peri-operative NMES) combined with standard rehabilitation in patients undergoing TKA surgery is better than the control group as measured by PASS at post-operative week 6. The investigators hypothesize that a significantly larger proportion of patients will indicate a positive PASS in the Kneehab XP group compared to the control group. Hypothesis 2:The investigators hypothesize that the mean change scores for pain, physical and functional performance measures will be significantly better for the Kneehab XP group at post operative week 6. Additionally, the investigators report the baseline corrected scores for these outcomes, as well as the primary and secondary outcomes, at all the other follow up time points. |
||||
| Detailed Description | Not Provided | ||||
| Study Type ICMJE | Interventional | ||||
| Study Phase | Phase 4 | ||||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
||||
| Condition ICMJE | Total Knee Replacement | ||||
| Intervention ICMJE |
|
||||
| Study Arm (s) |
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Recruiting | ||||
| Estimated Enrollment ICMJE | 118 | ||||
| Estimated Completion Date | March 2014 | ||||
| Estimated Primary Completion Date | March 2013 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 40 Years and older | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE |
|
||||
| Location Countries ICMJE | United States | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT01548040 | ||||
| Other Study ID Numbers ICMJE | Pro00012744 | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | Bio-Medical Research, Ltd. | ||||
| Study Sponsor ICMJE | Bio-Medical Research, Ltd. | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE | Not Provided | ||||
| Information Provided By | Bio-Medical Research, Ltd. | ||||
| Verification Date | March 2012 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||